Gao Jiang-Ping, Guo Wei, Zhang Hong-Peng
Department of Vascular Surgery, Chinese People's Liberation Army General Hospital, Medical School of Chinese People's Liberation Army, Beijing, China.
Department of Vascular Surgery, Chinese People's Liberation Army General Hospital, Beijing, China.
J Endovasc Ther. 2025 Jun;32(3):578-592. doi: 10.1177/15266028231187715. Epub 2023 Jul 21.
The objective of this systematic review was to assess the incidences and associations of early postoperative stroke and death among patients undergoing inner branched thoracic endovascular aortic repair (TEVAR) of arch pathologies.
Electronic bibliographic sources (PUBMED, EMBASE, and CENTRAL) were searched up to February 2022 using a combination of thesaurus and free-text terms to identify the studies using branched TEVAR to treat aortic arch disease. The systematic review was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. All observational studies investigating the prognosis of inner branched TEVAR in the treatment of aortic arch pathologies were included. Independent extraction of articles was performed by two authors using predefined data fields, including study quality indications. All pooled analyses were based on a random-effects or fixed model according to the heterogeneity.
A total of 23 case series totaling 532 participants were included after screening. After optimized selection (largest sample size, most detailed data, lowest risk of bias) from the overlapping data, 12 studies with 289 participants were included in data synthesis. The pooled incidence of 30-day postoperative stroke was 10.6% (95% CI 7.0%-14.2%; p=.41, I=3%). Pooled 30-day mortality was 4.9% (95% CI 2.0%-7.8%; p=.38, I=7%). Combined early stroke/death was 15.7% (95% CI 11.2%-20.3%; p=.30, I=15%). Subgroup analyses of 11 studies (without data missing) showed that a higher incidence of 30-day postoperative stroke was found in studies with aged participants (age≥71.3 years, p=.010), the higher percentage of COPD (≥30%, p= .011) and non-dissection-related pathologies (≥60.8%, p=.011). The higher 30-day postoperative mortality was found in studies with a high percentage of previous coronary artery disease (≥34.5%, p=.023).
This review demonstrated that there were acceptable rates of 30-day postoperative stroke and death among patients undergoing inner branched TEVAR. It is strongly necessary to perform a rigorous risk assessment of aortic plaque embolism and coronary artery disease when the surgical plan of the inner branched TEVAR is determined.Clinical ImpactTreatment arch pathologies with inner branched TEVAR provides acceptable early stroke rate and mortality. Aortic pathology mainly influenced the early stroke rate, and early recognizing high-risk patients for aortic plaque embolism is of supreme importance for reducing the early stroke rate. In addition, the history of coronary artery disease was strongly associated with early mortality, and attention should be paid to the coronary artery assessment and perioperative management of these patients.
本系统评价旨在评估接受主动脉弓病变腔内分支型胸主动脉腔内修复术(TEVAR)的患者术后早期卒中及死亡的发生率和相关性。
截至2022年2月,通过使用主题词和自由文本词相结合的方式检索电子文献来源(PUBMED、EMBASE和CENTRAL),以识别使用分支型TEVAR治疗主动脉弓疾病的研究。本系统评价按照系统评价和Meta分析的首选报告项目(PRISMA)指南进行。纳入所有调查腔内分支型TEVAR治疗主动脉弓病变预后的观察性研究。由两名作者使用预定义的数据字段独立提取文章,包括研究质量指标。所有汇总分析根据异质性基于随机效应或固定模型进行。
筛选后共纳入23个病例系列,总计532名参与者。在对重叠数据进行优化选择(最大样本量、最详细数据、最低偏倚风险)后,12项研究、289名参与者纳入数据合成。术后30天卒中的汇总发生率为10.6%(95%CI 7.0%-14.2%;p = 0.41,I² = 3%)。30天汇总死亡率为4.9%(95%CI 2.0%-7.8%;p = 0.38,I² = 7%)。早期卒中/死亡合并发生率为15.7%(95%CI 11.2%-20.3%;p = 0.30,I² = 15%)。11项研究(无数据缺失)的亚组分析显示,在有老年参与者(年龄≥71.3岁,p = 0.010)、慢性阻塞性肺疾病比例较高(≥30%,p = 0.011)和非夹层相关病变比例较高(≥60.8%,p = 0.011)的研究中,术后30天卒中发生率较高。在既往冠状动脉疾病比例较高(≥34.5%,p = 0.023)的研究中,术后30天死亡率较高。
本评价表明,接受腔内分支型TEVAR的患者术后30天卒中及死亡率在可接受范围内。在确定腔内分支型TEVAR手术方案时,对主动脉斑块栓塞和冠状动脉疾病进行严格的风险评估非常必要。临床影响腔内分支型TEVAR治疗主动脉弓病变可提供可接受的早期卒中率和死亡率。主动脉病变主要影响早期卒中率,早期识别主动脉斑块栓塞的高危患者对于降低早期卒中率至关重要。此外,冠状动脉疾病史与早期死亡率密切相关,应关注这些患者的冠状动脉评估和围手术期管理。